PDCD1 and neoplasm: It is plausible that a higher dose anti-PD1 could achieve anti-tumor responses as a peritumoral dose of around 1.2–1.5 mg/kg did not impact MB49 tumor growth while an IV administration of 4–5 mg/kg was curative [83].